250+ investors that invest in your industry and stage
Transportation
Gaming
Community
Proptech
FinTech
Biotech
Climate
Marketplace
Artificial intelligence
Energy
Hardware
Media (entertainment)
EdTech
Consumer
Health Care
Impact
Enterprise
Agriculture (agtech)
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Web3
Publishing
Clean Energy
Sporting Goods
Oil and Gas
B2B
Education
Organic Food
Big Data
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Video Games
Financial Services
Payments
Photography
Celebrity
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Franchise
Blockchain
Legal
Android
Social Impact
Mobile
Google
Construction
Sports
Local
eSports
Enterprise Software
Email
Wellness
Social Network
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Platforms
Biotechnology
Medical Device
Wine And Spirits
Automotive
Crowdfunding
Social
CleanTech
InsurTech
SaaS
Software
Film
Theatre
Life Science
Non Profit
Qatar
New Zealand
United States
South Korea
Germany
Australia
India
United Kingdom
Ireland
Canada
Africa
Asia
LATAM
Europe
Oceania
Middle East
China
South Africa
Singapore
Brazil
Japan
Indonesia
Sri Lanka
Vietnam
Spain
Saudi Arabia
Argentina
Armenia
Austria
Bangladesh
Bahrain
Belarus
Bulgaria
Belgium
Bermuda
Chile
Cameroon
Switzerland
Colombia
Belize
Costa Rica
Denmark
Ecuador
Algeria
Czech Republic
Georgia
Estonia
Egypt
Ghana
Hong Kong
Ethiopia
Gibraltar
Faroe Islands
Greece
Finland
Croatia
France
Hungary
Barbados
Kuwait
Italy
Jersey
Israel
Lebanon
Cambodia
Kenya
Cayman Islands
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Mali
Morocco
Norway
Malaysia
Mexico
Panama
Malta
Mauritius
Peru
Philippines
Nicaragua
Pakistan
Poland
Russian Federation
Romania
Sweden
Rwanda
Serbia
Seychelles
Turkey
Togo
Puerto Rico
Slovenia
Sierra Leone
San Marino
Senegal
Tunisia
Tanzania
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Thailand
Taiwan
Ukraine
Uruguay
Zimbabwe
Venezuela
Portugal
Azerbaijan
Bahamas
Guatemala
Iraq
Iceland
Namibia
Nigeria
United Arab Emirates
Honduras
Bolivia
Isle of Man
Luxembourg
Cyprus
Latvia
Oman
Angel investors
VC Funds
All investors
Download Find emails Save list

Top 50 Biotech Angel Investors in United Kingdom in October 2023

A list of 50 angel investors that invest in Biotech startups based in United kingdom. We rank investors based on the number of investments they made in Biotech companies from United kingdom. We update this investor list every month.

Top 50 Biotech Angel Investors in United Kingdom in October 2023

Investor Biotech United Kingdom investments
Jonathan Milner 25
Nadav Rosenberg 5
Darrin Disley 4
Stefano Bernardi 3
Ian Hogarth 3
Milad Alucozai 3
Jude Gomila 3
DrPano Kroko Churchill 3
Peder Nielsen 3
Edward Lando 2
Jim Mellon 2
Ariel Poler 2
Pratima Aiyagari 2
Patrick Pichette 2
Jon Oringer 2
Hugh Grant 2
Serge Chiaramonte 2
Paul Wicks 2
Paul Forster 2
Nadav Ben-Chanoch 2
Jon Oringer 2
Jon Oringer 2
Jan Hruska 2
Nicholas Edwards 2
Ed Parkinson 2
Charlie Songhurst 2
Gilad Engel 2
Nick Boyle 2
Mark Evans 2
Inaki Berenguer 2
Chris Mairs 2
Tim Dempsey 2
Rick Bernstein 1
Pa Nolan 1
Oliver Sexton 1
Fiona Pathiraja 1
Declan Doogan 1
Sami Mikati 1
Aydın Öztunalı 1
Sunil Shah 1
Kristen Fortney 1
Karl Wills 1
Hugo Amsellem 1
Jim Warwick 1
Marcus East 1
David Ebsworth 1
Martin Chavez 1
Susan Lowther 1
Margaret Georgiadis 1
Andrew J M Richards 1

Get 300+ niche investors in 2 minutes.

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Trusted by 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck
Investor list
Jonathan Milner
Angel · Cambridge, Massachusetts, United States · 4 investments in the past 12 months

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United Kingdom, United States, Canada

Portfolio highlights

  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
  • Pencil Biosciences — Next Generation Genome Editing Tool
Show more investments...

Nadav Rosenberg
Angel · London, England, United Kingdom · 3 investments in the past 12 months

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Show more...

Investment focus

  • Biotechnology, Artificial Intelligence, Pharmaceutical
  • Seed, Pre-Seed, Series A
  • United Kingdom, Israel, Singapore

Portfolio highlights

  • thymia — Making mental health as objectively measurable as physical health.
  • Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
  • Loops — Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data.
Show more investments...

Darrin Disley
Angel · Cambridge, Cambridgeshire, United Kingdom

Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.

Show more...

Investment focus

  • Biotechnology, Health Care, Big Data
  • Seed, Series A, Funding Round
  • United Kingdom

Portfolio highlights

  • bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Show more investments...

Stefano Bernardi
Angel · San Francisco, California, United States · 3 investments in the past 12 months

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Show more...

Investment focus

  • Software, Biotechnology, Cryptocurrency
  • Seed, Pre-Seed, Funding Round
  • Italy, France, Norway

Portfolio highlights

  • Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
  • Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
  • CaSRevolution — A novel disease-modifying approach against neurodegeneration
Show more investments...

Ian Hogarth
Angel · London, England, United Kingdom

Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.

Show more...

Investment focus

  • Software, E-Commerce, Health Care
  • Seed, Pre-Seed, Series A
  • United Kingdom, United States, Germany

Portfolio highlights

  • Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
  • The Garden — The Garden is an online media company.
  • Condense — Live-streamed volumetric video into game engines
Show more investments...

Milad Alucozai
Angel · San Francisco, California, United States · 4 investments in the past 12 months

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Seed, Series A, Pre-Seed
  • United States, Canada, United Kingdom

Portfolio highlights

  • Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
  • Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
  • Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
Show more investments...

Jude Gomila
Angel · San Francisco, California, United States · 5 investments in the past 12 months

Jude Gomila is currently CEO and Founder of the startup Golden.

Show more...

Investment focus

  • Software, Biotechnology, Information Technology
  • Seed, Pre-Seed, Angel
  • United States, United Kingdom, Canada

Portfolio highlights

  • Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
  • Monitaur — Reduce operational overhead, improve security, optimize performance, and deliver amazing customer experiences with our end-to-end, hybrid observability & APM platform built for decentralized apps and infrastructure.
  • Gradia Health — Gradia is an integrated, concierge care platform designed for clinics to support patients with chronic conditions.
Show more investments...

DrPano Kroko Churchill
Angel · Seattle, Washington, United States

Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com

Show more...

Investment focus

  • Health Care, Therapeutics, Biotechnology
  • Angel, Series A
  • United Kingdom

Portfolio highlights

  • Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Show more investments...

Peder Nielsen
Angel · Copenhagen, Hovedstaden, Denmark · 2 investments in the past 12 months

Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund

Show more...

Investment focus

  • Biotechnology, Machine Learning
  • Seed, Funding Round
  • United Kingdom

Portfolio highlights

  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Show more investments...

Edward Lando
Angel · San Francisco, California, United States · 17 investments in the past 12 months

Edward Lando is the Managing Partner at Pareto Holdings.

Show more...

Investment focus

  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Funding Round
  • United States, France, United Kingdom

Portfolio highlights

  • micro1 — We help companies hire and manage the best software engineers easily.
  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show more investments...

Jim Mellon
Angel · 3 investments in the past 12 months

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Show more...

Investment focus

  • Biotechnology, Health Care, Food and Beverage
  • Series A, Seed, Funding Round
  • United States, United Kingdom, Israel

Portfolio highlights

  • Amy — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
  • Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
  • The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Show more investments...

Ariel Poler
Angel · San Francisco, California, United States

Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.

Show more...

Investment focus

  • Software, Social Media, Internet
  • Seed, Series A, Angel
  • United States, Mexico, United Kingdom

Portfolio highlights

  • Reloadly — Reloadly is the #1 mobile top-up platform when it comes to developer-friendly technology. With our API and a few lines of code, you can easily integrate mobile top-up features into your website or mobile app.
  • Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
  • humm — humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.humm is working to bring the incredible results of neuroscience research out of the lab and into non-invasive wearables that improve the quality of life for everyday people. Our first product is a clinically validated patch that you wearfor 15 minutes to get up to 90 minutes of improved working memory, by gently stimulating the signals in the part of the brain that controls your executive thinking. humm improves your ability to learn and be at your best, allowing people to reconnect with the joy of learning and challenge themselves to continue growing at any stage of life, whether it's for work or personal enjoyment!
Show more investments...

Pratima Aiyagari
Angel · London, England, United Kingdom

Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.

Show more...

Investment focus

  • Analytics, Information Technology, Software
  • Pre-Seed, Seed, Series A
  • United Kingdom, France, Croatia

Portfolio highlights

  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
  • NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
  • Treblle — Treblle is a lightweight SDK that helps Engineering and DevOps teams build, ship & maintain REST based APIs faster
Show more investments...

Patrick Pichette
Angel · London, England, United Kingdom · 2 investments in the past 12 months

Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A  MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).

Show more...

Investment focus

  • Artificial Intelligence, Machine Learning, Software
  • Seed, Series B, Series A
  • United Kingdom, Germany, United States

Portfolio highlights

  • Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.
  • Unlikely AI — We are pioneering safe, trustworthy and powerful artificial intelligence
  • Vay — Vay is a leading teledriving company that aims to launch a unique, affordable, and sustainable door-to-door mobility service.
Show more investments...

Jon Oringer
Angel · Miami, Florida, United States · 4 investments in the past 12 months

Jon Oringer is the founder and chairman of Shutterstock.

Show more...

Investment focus

  • Software, Information Technology, E-Commerce
  • Seed, Pre-Seed, Funding Round
  • United States, United Kingdom, France

Portfolio highlights

  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • Zamp — We give you freedom from sales tax! Eliminate the need to learn, manage or touch any part of the sales tax compliance process.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show more investments...

Hugh Grant
Angel · Saint Louis, Missouri, United States · 1 investment in the past 12 months

Hugh Grant is President and Chief Executive Officer at Monsanto.

Show more...

Investment focus

  • Biotechnology, Machine Learning
  • Seed, Funding Round
  • United Kingdom

Portfolio highlights

  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Show more investments...

Serge Chiaramonte
Angel · London, England, United Kingdom · 1 investment in the past 12 months

Serge Chiaramonte

Show more...

Investment focus

  • FinTech, Financial Services, E-Commerce
  • Seed, Pre-Seed, Series A
  • United Kingdom, United States, China

Portfolio highlights

  • Trezy — Trezy is smart & simple software the helps you manage your business with real-time finance insights & automated cash-flow forecasting.
  • Basket — Basket lets you keep track of things you want to buy, automatically finding the best prices, saving you time and money. Say hello to your new shopping companion.
  • Klasha — At Klasha, we're simplifying borderless payments for commerce in Africa. We help merchants worldwide sell online to Africa and receive payments in local African currencies while enjoying super fast last-mile delivery to customers across the continent.
Show more investments...

Paul Wicks
Angel · London, England, United Kingdom

Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.

Show more...

Investment focus

  • Real Time, Marketplace, Biotechnology
  • Seed, Series A
  • United Kingdom

Portfolio highlights

  • Sano Genetics — The future of precision medicine is here. Deep dive into your DNA & contribute to the latest research opportunities. Discover Sano Genetics.
Show more investments...

Paul Forster
Angel · 7 investments in the past 12 months

Paul Forster

Show more...

Investment focus

  • Software, FinTech, Financial Services
  • Seed, Series A, Pre-Seed
  • United Kingdom, Germany, Spain

Portfolio highlights

  • Outverse — A community platform that's easier to use, better organised and designed for real interaction.
  • CultureAI — Measure and improve human cyber risks and security behaviours to prevent security incidents. Go beyond security awareness training, start your free trial today.
  • finway — finway provides financial guidence to SMEs, plan & control all expenses and budgets in one tool.
Show more investments...

Nadav Ben-Chanoch
Angel · Miami, Florida, United States · 12 investments in the past 12 months

Nadav Ben-Chanoch - Partner @ Pareto Holdings

Show more...

Investment focus

  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Funding Round
  • United States, United Kingdom, France

Portfolio highlights

  • Swaap — We build the market-neutral AMM protocol.
  • micro1 — We help companies hire and manage the best software engineers easily.
  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
Show more investments...

Jon Oringer
Angel · Miami, Florida, United States · 3 investments in the past 12 months

Jon Oringer is the founder and chairman of Shutterstock.

Show more...

Investment focus

  • Software, Information Technology, E-Commerce
  • Seed, Pre-Seed, Funding Round
  • United States, France, United Kingdom

Portfolio highlights

  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • Zamp — We give you freedom from sales tax! Eliminate the need to learn, manage or touch any part of the sales tax compliance process.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show more investments...

Jon Oringer
Angel · New York, New York, United States · 3 investments in the past 12 months

Jon Oringer is the founder and chairman of Shutterstock.

Show more...

Investment focus

  • Software, Information Technology, Health Care
  • Seed, Pre-Seed, Series A
  • United States, France, United Kingdom

Portfolio highlights

  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • Zamp — We give you freedom from sales tax! Eliminate the need to learn, manage or touch any part of the sales tax compliance process.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show more investments...

Jan Hruska
Angel

Jan Hruska

Show more...

Investment focus

  • Medical, Health Care, Life Science
  • Seed, Funding Round
  • United Kingdom

Portfolio highlights

  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Show more investments...

Nicholas Edwards
Angel · Oxford, Oxfordshire, United Kingdom

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Show more...

Investment focus

  • Medical, Health Care, Life Science
  • Seed, Funding Round
  • United Kingdom

Portfolio highlights

  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Show more investments...

Ed Parkinson
Angel

Ed Parkinson

Show more...

Investment focus

  • Software, Health Care, Life Science
  • Seed
  • United Kingdom

Portfolio highlights

  • Antiverse — Designing biologics for 100 challenging targets
Show more investments...

Charlie Songhurst
Angel · Greater Seattle Area, Washington, United States · 20 investments in the past 12 months

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.

Show more...

Investment focus

  • Software, Information Technology, Artificial Intelligence
  • Seed, Pre-Seed, Series A
  • United States, United Kingdom, Germany

Portfolio highlights

  • Hubflo — Hubflo is building an all-in-one work OS to help small businesses manage their business. Instead of having 10 complicated and expensive pieces of software, Hubflo offers SMB everything they need to run their business (CRM, projects, invoicing, expenses...) in a single comprehensive, simple and affordable platform.
  • Story Protocol — Story Protocol is building open IP infrastructure to grow the creativity of the internet era.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Show more investments...

Gilad Engel
Angel

Gilad Engel - Partner @ Target Global

Show more...

Investment focus

  • Analytics, Biotechnology, Financial Services
  • Seed, Pre-Seed
  • France, United Kingdom

Portfolio highlights

  • Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Show more investments...

Nick Boyle
Angel · London, England, United Kingdom

In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.

Show more...

Investment focus

  • Biofuel, Agriculture, Artificial Intelligence
  • Seed
  • United Kingdom

Portfolio highlights

  • Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
  • Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Show more investments...

Mark Evans
Angel · London, England, United Kingdom

Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.

Show more...

Investment focus

  • Software, E-Commerce, Health Care
  • Funding Round, Series A, Seed
  • United Kingdom, United States, The Netherlands

Portfolio highlights

  • ONI — ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life.
  • Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
  • Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Show more investments...

Inaki Berenguer
Angel · New York, New York, United States

Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.

Show more...

Investment focus

  • E-Commerce, FinTech, Enterprise Software
  • Seed, Angel, Pre-Seed
  • Spain, United States, United Kingdom

Portfolio highlights

  • Paack — Find the ideal delivery solution to integrate to your e-commerce. We adapt to your retail, offering your customer an amazing delivery experience.
  • Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
  • Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.
Show more investments...

Chris Mairs
Angel · London, England, United Kingdom · 3 investments in the past 12 months

Chris Mairs - Venture Partner @ Entrepreneur First

Show more...

Investment focus

  • Software, FinTech, Financial Services
  • Seed, Pre-Seed, Angel
  • United Kingdom, United States

Portfolio highlights

  • Pathway — LLM-enabled financial research at the speed of thought.
  • Statement — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Show more investments...

Tim Dempsey
Angel

Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.

Show more...

Investment focus

  • Software, SaaS, Information Technology
  • Seed, Series A, Funding Round
  • United Kingdom

Portfolio highlights

  • Lunio — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
  • Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
  • PPC Protect — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
Show more investments...

Rick Bernstein
Angel · North Myrtle Beach, South Carolina, United States

Rick Bernstein is the Chief Commercial Officer for MedNet responsible for the development of the commercial infrastructure and strategy for MedNet, a healthcare technology company specializing in eClinical solutions for the global life sciences industry. Rick is currently leading the development of an optimized sales, business development, anddistribution strategy to drive aggressive growth across key market segments, including CROs and pharmaceutical, medical device and biotechnology sponsors.

Show more...

Investment focus

  • Health Care, Biotechnology, Agriculture/Farming
  • Seed
  • United Kingdom

Portfolio highlights

  • Phytoform Labs — Phytoform Labs is improving crops to make agriculture more sustainable and nutritious
Show more investments...

Pa Nolan
Angel

Pa Nolan

Show more...

Investment focus

  • Software, Transportation, Commerce/Shopping
  • Funding Round
  • Ireland

Portfolio highlights

  • SiSaf — SiSaf delivers on the promise of RNA therapeutics with Bio-Courier technology.
  • Scurri — Scurri is next generation delivery management software that puts retailers back in control. Explore our delivery management software today.
Show more investments...

Oliver Sexton
Angel · London, England, United Kingdom · 3 investments in the past 12 months

Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.

Show more...

Investment focus

  • Biotechnology, Health Care, Life Science
  • Seed, Pre-Seed, Funding Round
  • United Kingdom

Portfolio highlights

  • MicrofluidX — Delivering the next generation of automated cell and gene therapy manufacturing platforms to bring precision medicine to patients
  • Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
  • Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Show more investments...

Fiona Pathiraja
Angel · 5 investments in the past 12 months

Fiona is Managing Partner at Crista Galli Ventures, an early stage healthtech VC fund based in London and Copenhagen.

Show more...

Investment focus

  • Health Care, Science/Engineering, Software
  • Seed, Pre-Seed, Series A
  • United Kingdom, Germany, Armenia

Portfolio highlights

  • Daye — Organic, super absorbent, sustainable tampons for when your period is cramping your style. ProViotics for vaginal health. We deliver sustainable products that work hard to help you feel your best, whatever life brings.
  • Melon — Save & organise content from any source. Follow experts and friends. Share your knowledge with others.
  • Holly Health — Rebuild your relationship with food and manage your stress with Holly Health, your personalised health coach.
Show more investments...

Declan Doogan
Angel · Douglas, NA - Isle of Man, Isle of Man · 1 investment in the past 12 months

Declan Doogan has over 30 years of industry experience in both major pharma and biotech.He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Sinceleaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo).Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.

Show more...

Investment focus

  • Health Care, Biotechnology, Science/Engineering
  • Seed, Series A, Funding Round
  • United States, United Kingdom

Portfolio highlights

  • Causeway Therapeutics — A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies.
  • Intensity Therapeutics — Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors AND induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease.
Show more investments...

Sami Mikati
Angel

Sami Mikati is a Director of Synthace Ltd. Investor and commercial executive with deep experience and network across energy and engineering industries in Europe, the Middle East and Africa.

Show more...

Investment focus

  • Biotechnology, Software, Life Science
  • Seed
  • India, United Kingdom

Portfolio highlights

  • CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
  • Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Show more investments...

Aydın Öztunalı
Angel

Aydın Öztunalı

Show more...

Investment focus

  • Software, Apps, Mobile
  • Seed, Angel
  • Turkey, United States, United Kingdom

Portfolio highlights

  • Evreka — Evreka is a leading SaaS company providing the most comprehensive intelligent solutions designed for the entire category of waste management across the globe.
  • Initio — initio is Enabling the transformation of the pharmaceutical industry today by using lab-on-a-chip and organ-on-a-chip technologies
  • Otsimo — Otsimo offers special education and speech therapy apps for autism, down syndrome and other developmental disabilities. Click to see our autism apps!
Show more investments...

Sunil Shah
Angel · Cambridge, Cambridgeshire, United Kingdom

Sunil Shah is the CEO and Co-Founder of o2h group. He previously worked at India-UK Cancer Research Initiative (CRUK-DBT) as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.

Show more...

Investment focus

  • Health Care, Biotechnology, Science/Engineering
  • Seed, Series A, Post-IPO Equity
  • United Kingdom

Portfolio highlights

  • Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
  • PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
  • Spirea Ltd. — Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
Show more investments...

Kristen Fortney
Angel · San Francisco, California, United States · 1 investment in the past 12 months

Kristen Fortney - CEO & Co-Founder @ BIOAGE LABS

Show more...

Investment focus

  • Biopharma, Health Care, Therapeutics
  • Series A
  • United Kingdom

Portfolio highlights

  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Show more investments...

Karl Wills
Angel

Originally at MetaPack in 2000, Karl returned in November 2009 to take on the role as COO and CIO responsible for MetaPack’s Product Development, Support, Infrastructure and Carrier Integration. Karl is now responsible for handling MetaPack's legal activity and ensuring best practice is brought into all parts of the MetaPack operation toensure exceptional performance for our customers. In between the MetaPack roles, he worked for Abacus Billing as CEO before its sale to Mind CTI, successfully managing the company turnaround at Solution 1 as COO and interim CEO where he focused on improving their delivery function as well as their IT infrastructure.Prior to joining MetaPack that he has held roles such as Senior Supply Chain Director for EMI Records (based in The Netherlands), IT Director for EMI Operations and IT Director EMI France as well as a number of other UK and European IT and Logistics roles. This provides Karl with over 30 years experience in general management and the IT, logistics and warehouse industry.

Show more...

Investment focus

  • CRM, Farming, Agriculture
  • Seed
  • United Kingdom

Portfolio highlights

  • Bionema — Leading UK biopesticides technology developer, specialising in organic chemical-free, biological crop protection for safe and sustainable agriculture.
Show more investments...

Hugo Amsellem
Angel · Berlin, Berlin, Germany · 3 investments in the past 12 months

Investing in consumer stuff (content, community, commerce, creators). Advisor at Jellysmack, previously Founding Team at The Family

Show more...

Investment focus

  • Software, Financial, IT
  • Seed, Pre-Seed
  • United States, France, United Kingdom

Portfolio highlights

  • Figures — Figures delivers reliable, up-to-date salary and equity data, allowing the people professionals to plan and benchmark their compensation plan
  • Aria — TELL BEAUTIFUL STORIES
  • Intros AI — Intros is a developer of a communication platform to help people communicate within the community. Its platform also allows people to talk with each other through direct messaging or in interest groups and automate introductions between their members. Through this software, users feel more connected and supported while helping communities scaletheir personalized introductions.The company was founded in 2020 and is headquartered in Danvers, Massachusetts.
Show more investments...

Jim Warwick
Angel · Cambridge, Cambridgeshire, United Kingdom

Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.

Show more...

Investment focus

  • Life Science, Biotechnology
  • Seed
  • United Kingdom

Portfolio highlights

  • Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
Show more investments...

Marcus East
Angel · Greater Seattle Area, Washington, United States

Marcus East is an international technology and product executive and CDO/CIO/CTO with over 25 years experience of working in the Information Technology, specializing in, Digital Product, Digital Transformations and Electronic Commerce. He has two degrees: a Bachelor’s with honors in Management & Information Technology (Modular) fromLondon Guildhall and a Master’s in Management from the University of Cambridge. He is also a full member of the Chartered Management Institute, a Fellow of the British Computer Society Chartered Institute for IT, and holds the IoD Certificate in Company Direction. Marcus started his career with IBM where he spent six years honing his consulting and strategy skills, before joining Omnicom’s agency.com where he spent two years learning about the importance of user experience, and further developed his management skills. Since then, he has held senior digital leadership positions for a number of major brands, including Comic Relief, Apple and National Geographic.

Show more...

Investment focus

  • Software, Health Care, Biotechnology
  • Seed
  • United Kingdom

Portfolio highlights

  • OxCan — Enabling curative cancer treatment through early detection
Show more investments...

David Ebsworth
Angel · Zürich, Zurich, Switzerland

Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s ExecutiveCommittee, positions he held until August 2014. Dr. Ebsworth received a PhD in industrial relations from the University of Surrey.

Show more...

Investment focus

  • Pharmaceutical, Biopharma, Health Care
  • Seed, Post-IPO Equity
  • United Kingdom

Portfolio highlights

  • Small Pharma — Small Pharma is a biotechnology company researching and developing short-duration psychedelics with therapy for under-served mental health conditions.
  • Verona Pharma — Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.
Show more investments...

Martin Chavez
Angel · New York, New York, United States · 2 investments in the past 12 months

Marty Chavez is executive vice president and chief financial officer of The Goldman Sachs Group, Inc. He is a member of the Management Committee, Firmwide Capital Committee, Firmwide Risk Committee and Steering Committee on Regulatory Reform. Marty is also a member of the Firmwide Hispanic/Latino Network and the Lesbian, Gay, Bisexual andTransgender Network.Marty first joined Goldman Sachs in 1993 in the J. Aron Currency and Commodities Division, where he was a senior energy strat until 1997. He returned to the firm as a managing director in Investment Banking Division Strats in 2005, becoming global co-head of Securities Division Strats and then global co-chief operating officer of the Equities Franchise. Prior to assuming his current role, Marty was chief information officer, responsible for the Technology Division and jointly responsible with divisional leadership for the firm’s global strategists. He was named partner in 2006.Prior to first joining the firm, Marty was co-founder and chief technology officer of Quorum Software Systems from 1989 to 1993. From 1997 to 2000, he was global head of energy derivatives at Credit Suisse Financial Products. In 2000, Marty co-founded Kiodex, Inc. and was chairman and chief executive officer until 2004.Marty serves on the Harvard Board of Overseers and is a Fellow of the New York Academy of Medicine.Marty earned a PhD in Medical Information Sciences from Stanford University in 1990, an SM in Computer Science from Harvard University in 1985, and an AB, magna cum laude, in Biochemical Sciences from Harvard College in 1985.

Show more...

Investment focus

  • Health Care, Machine Learning, Biotechnology
  • Series A, Seed, Private Equity
  • United States, United Kingdom

Portfolio highlights

  • Hebbia — Hebbia's neural search lets you execute research 10X faster and 10X more accurately. Transform your productivity today.
  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
  • VMind AI — VMind is a frontier technology company building artificial general intelligence (AGI).
Show more investments...

Susan Lowther
Angel · Cambridge, Cambridgeshire, United Kingdom · 2 investments in the past 12 months

Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc andFinance Director of RiboTargets Limited until its acquisition by Vernalis plc.

Show more...

Investment focus

  • Education, Health Care, Biotechnology
  • Funding Round, Post-IPO Equity
  • United Kingdom

Portfolio highlights

  • Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Show more investments...

Margaret Georgiadis
Angel · San Francisco, California, United States · 2 investments in the past 12 months

Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University

Show more...

Investment focus

  • Health Care, Apps, Wellness
  • Seed, Series A, Series B
  • United States, United Kingdom

Portfolio highlights

  • OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
  • ShareWell — Struggling with mental health issues? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
  • Bridge Money — The path towards upward economic mobility.
Show more investments...

Andrew J M Richards
Angel · 2 investments in the past 12 months

Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies.

Show more...

Investment focus

  • Biopharma, Education, Biotechnology
  • Funding Round, Post-IPO Equity
  • United Kingdom

Portfolio highlights

  • Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Show more investments...
Investors by industry
Investors by country
Angel Investors in United Kingdom by industry

Close your round

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Join 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck